Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HOLX vs RMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RMD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

RMD Overall Winner 6-Pillar Tally: HOLX 2 – 4 RMD Matrix Metrics: HOLX 3 – 7 RMD

As of Nov 20, 2026, ResMed Inc. (RMD) is the stronger overall head-to-head candidate over Hologic Inc (HOLX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas RMD carries 61.9/100 (BUY) at $235.63 (19.5x Forward P/E, 34.0% operating margin).

  • Composite vs. Pillar Nuance: While HOLX currently prints a higher short-term Unified Composite Score (64.2/100 BUY vs. RMD 61.9/100 BUY), RMD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 23.0% operating margin) and revenue trajectory (+5.9% vs. +2.5% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HOLX vs RMD
HOLX NASDAQ
Hologic Inc
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$76.01
+0.48% 1D
Market Cap $16.9B
TTM Revenue $4.13B
Forward P/E 20.1x
Beta / 30D Vol 0.08β · 3% Vol
Unified Composite Score
64.2 / 100 BUY
Tech 75.0 Fund 61.0 Flow 54.0 Mom 49.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 69.0 · SMA20: $75.47 · SMA50: $75.29
RMD NYSE Head-to-Head Winner
ResMed Inc.
Surgical & Medical Instruments & Apparatus
$235.63
-0.53% 1D
Market Cap $33.3B
TTM Revenue $5.73B
Forward P/E 19.5x
Beta / 30D Vol 0.39β · 41% Vol
Unified Composite Score
61.9 / 100 BUY
Tech 57.0 Fund 60.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.6 · SMA20: $239.50 · SMA50: $233.84

6-Pillar Scorecard Institutional Category Breakdown (HOLX 2 – 4 RMD)

Columns: Metric · HOLX · RMD
1. Valuation Multiples RMD
Forward P/E 20.1x 19.5x
Trailing P/E 31.4x 21.6x
PEG Ratio 1.66x 1.30x
EV / Revenue 4.1x 5.7x
2. Growth & Scale RMD
Revenue Growth (YoY) +2.5% +5.9%
Earnings Growth (YoY) -9.2% +23.2%
TTM Revenue (USD) $4.13B $5.73B
Market Cap $16.9B $33.3B
3. Profitability & Quality RMD
Gross Margin 60.4% 61.8%
Operating Margin 23.0% 34.0%
Net Profit Margin 13.2% 27.8%
Return on Equity (ROE) 10.9% 26.4%
4. Balance Sheet & Cash Flow HOLX
Cash Generation (TTM) $1.35B EBITDA $1.59B
Cash Flow Margin 32.7% EBITDA Mgn 27.7%
Net Cash / Leverage $23.51 Book/Sh · 10.9% ROE $400M Net Cash
Dividend Yield None (0.00%) 1.01%
5. Options & Positioning RMD
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 6.3% (3rd %ile) 90.6% (100th %ile)
Put/Call OI Skew 6.20x (Put-Skewed) 4.01x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat HOLX
OpEx & R&D Intensity 37.4% of Rev ($1.54B) 27.8% of Rev ($1.59B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HOLX (3) vs RMD (7)
Institutional Metric HOLX RMD Criterion Row Edge
Market Capitalization
Scale
$16.9B $33.3B Larger Scale RMD
Trailing P/E Ratio
Valuation
31.4x 21.6x Lower Multiple RMD
Forward P/E Ratio
Valuation
20.1x 19.5x Lower Multiple RMD
Revenue Growth (YoY)
Growth
+2.5% +5.9% Higher Growth RMD
Operating Margin (TTM)
Profitability
23.0% 34.0% Higher Margin RMD
Net Profit Margin
Profitability
13.2% 27.8% Higher Margin RMD
Return on Equity (ROE)
Capital Efficiency
10.9% 26.4% Higher ROE RMD
52-Week Range Position
Momentum
100% ($52–$76) 57% ($180–$278) Stronger Trend HOLX
Beta / 30D Volatility
Risk Regime
0.08β · 3% Vol 0.39β · 41% Vol Lower Realized Risk HOLX
Unified Institutional Score
Composite Signal
64.2 / 100 (BUY) 61.9 / 100 (BUY) Higher Composite HOLX
Trailing 12M Revenue (USD)
Operating Scale
$4.13B $5.73B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.4% 61.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.66x PEG · 4.1x EV/Rev 1.30x PEG · 5.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.35B EBITDA ($23.51 Book/Sh · 10.9% ROE) $1.59B ($400M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HOLX +12.24 pp
HOLX: +0.34% · RMD: -11.9%
3M Horizon HOLX +10.06 pp
HOLX: +1.94% · RMD: -8.12%
6M Horizon HOLX +10.67 pp
HOLX: +2.48% · RMD: -8.19%
1Y Horizon HOLX +10.67 pp
HOLX: +2.48% · RMD: -8.19%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HOLX vs RMD. Trailing 12-month operating profitability (HOLX 23.0% vs RMD 34.0%) and valuation multiples (HOLX 20.1x vs RMD 19.5x Forward P/E) are benchmarked directly in Pillar 4 below.

HOLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.13B
Gross Margin60.4%
Op. Margin23.0%
ROE / Fwd P/E10.9% · 20.1x
RMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.73B
Gross Margin61.8%
Op. Margin34.0%
ROE / Fwd P/E26.4% · 19.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HOLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 6.3%
IV Percentile 3rd %ile
Put/Call OI Skew 6.20x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact HOLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RMD CONSOLIDATION
62d in phase · OBV DISTRIBUTION
Current IV 90.6%
IV Percentile 100th %ile
Put/Call OI Skew 4.01x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact RMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $238.19 · IV 29.8%

RMD Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($23,819)

Compare $23,819 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 29.8% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $240 / $250 Bull Call Spread

Buy 1x $240C · Sell 1x $250C · 31d

Net Entry $540 Debit
T+5d @ +5% Move +$188 (+35%)
Max Risk / Buffer $540 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $230 / $220 Bull Put Spread

Sell 1x $230P · Buy 1x $220P · 31d

Net Entry $241 Credit
Max Credit / Yield +$241 (+31.8% RoM)
Max Risk / Buffer -4.5% Cushion ($759 Mgn)
5d Edge & Liquidity 69% PoP · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HOLX Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $16.9B market capitalization and 23.0% operating margin.
OpEx & R&D Reinvestment 37.4% of Rev ($1.54B)
90D Engineering Disclosures 0 Published
RMD Moat Profile High-Margin Pricing Power Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $33.3B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 27.8% of Rev ($1.59B)
90D Engineering Disclosures 0 Published

Investor FAQ HOLX vs RMD Key Questions & Quantitative Answers

As of Nov 20, 2026, ResMed Inc. (RMD) is the stronger overall head-to-head candidate over Hologic Inc (HOLX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas RMD carries 61.9/100 (BUY) at $235.63 (19.5x Forward P/E, 34.0% operating margin). Composite vs. Pillar Nuance: While HOLX currently prints a higher short-term Unified Composite Score (64.2/100 BUY vs. RMD 61.9/100 BUY), RMD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 23.0% operating margin) and revenue trajectory (+5.9% vs. +2.5% YoY).

RMD leads the Growth & Scale pillar: HOLX posts +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin), compared with RMD at +5.9% YoY revenue growth and +23.2% YoY earnings growth on $5.73B TTM revenue (61.8% gross margin, 34.0% operating margin). On trailing 12-month operating scale, HOLX generates $4.13B in USD-normalized revenue versus $5.73B for RMD. In operating R&D and SG&A reinvestment, HOLX deploys 37.4% of Rev ($1.54B) (0 90-day corporate R&D disclosures) versus 27.8% of Rev ($1.59B) (0 disclosures) for RMD.

RMD screens cheaper on headline valuation multiples. HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin), whereas RMD trades at 19.5x Forward P/E, 21.6x Trailing P/E, 1.30x PEG, and 5.7x EV/Revenue (27.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HOLX (10.9% ROE) versus RMD (26.4% ROE) capital efficiency.

In options market volatility and institutional positioning, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk). By comparison, RMD carries 90.6% implied volatility (100th %ile, Extreme (>80th %ile)), a 4.01x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.39β · 41% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.